Explanipedia

Precision-cut tumor slices for modeling hepatocellular carcinoma enable at-scale drug screening Open

Amy Collins, Keara Kirkness, Erik Ramon‐Gil, Eleni Tzortzopoulou, Daniel Geh , et al. · 2025

Background: Disease modeling is vital for our understanding of disease mechanisms and for developing new therapeutic strategies. Accurately modeling the intact tumor microenvironment (TME) is increasingly recognized as essential for gainin…

ST3 beta-galactoside alpha-2,3-sialyltransferase 1 (ST3Gal1) synthesis of Siglec ligands mediates anti-tumour immunity in prostate cancer Open

Rebecca Garnham, Daniel Geh, Ryan Nelson, Erik Ramon‐Gil, Laura Wilson , et al. · 2024

Immune checkpoint blockade has yet to produce robust anti-cancer responses for prostate cancer. Sialyltransferases have been shown across several solid tumours, including breast, melanoma, colorectal and prostate to promote immune suppress…

Harnessing neutrophil plasticity for HCC immunotherapy Open

Erik Ramon‐Gil, Daniel Geh, Jack Leslie · 2023

Neutrophils, until recently, have typically been considered a homogeneous population of terminally differentiated cells with highly conserved functions in homeostasis and disease. In hepatocellular carcinoma (HCC), tumour-associated neutro…

Impact of COVID-19 on 1-Year Survival Outcomes in Hepatocellular Carcinoma: A Multicenter Cohort Study Open

Shuell De Souza, Jeffrey Kahol de Jong, Ylenia Perone, Shishir Shetty, Maria Qurashi , et al. · 2023

Introduction: The COVID-19 pandemic has caused severe disruption of healthcare services worldwide and interrupted patients’ access to essential services. During the first lockdown, many healthcare services were shut to all but emergencies.…

ST3Gal1 synthesis of Siglec ligands mediates anti-tumour immunity in prostate cancer Open

Rebecca Garnham, Daniel Geh, Ryan Nelson, Erik Ramon-Gill, Laura Wilson , et al. · 2023

Immune checkpoint blockade trials have yet to produce a robust anti-cancer response in prostate cancer patients as a monotherapy due to the immunosuppressed prostate cancer tumour immune microenvironment. ST3Gal1 and other sialyltransferas…

Impact of COVID19 on clinical outcomes in hepatocellular carcinoma:A multicentre cohort study Open

Shuell De Souza, Jeffery Kahol de Long, Ylenia Perone, Shishir Shetty, Maria Qurashi , et al. · 2022

Introduction: The COVID-19 pandemic has caused severe disruption of healthcare services worldwide and interrupted patients’ access to essential services. During the first lockdown, many healthcare services were shut to all but emergencies.…

c‐Rel–dependent Chk2 signaling regulates the DNA damage response limiting hepatocarcinogenesis Open

Jack Leslie, Jill V. Hunter, Amy Collins, Amelia Rushton, Lauren G. Russell , et al. · 2022

Background and Aims: Hepatocellular carcinoma (HCC) is a leading cause of cancer‐related death. The NF‐κB transcription factor family subunit c‐Rel is typically protumorigenic; however, it has recently been reported as a tumor suppressor. …

CXCR2 inhibition enables NASH-HCC immunotherapy Open

Jack Leslie, John B. G. Mackey, Thomas Jamieson, Erik Ramon‐Gil, Thomas M. Drake , et al. · 2022

Objective Hepatocellular carcinoma (HCC) is increasingly associated with non-alcoholic steatohepatitis (NASH). HCC immunotherapy offers great promise; however, recent data suggests NASH-HCC may be less sensitive to conventional immune chec…

COVID-19 and liver cancer: lost patients and larger tumours Open

Daniel Geh, Robyn Watson, Gourab Sen, Jeremy French, John Hammond , et al. · 2022

Background Northern England has been experiencing a persistent rise in the number of primary liver cancers, largely driven by an increasing incidence of hepatocellular carcinoma (HCC) secondary to alcohol-related liver disease and non-alco…

CXCR2 inhibition enables NASH-HCC immunotherapy Open

Jack Leslie, John B. G. Mackey, Thomas Jamieson, Erik Ramon‐Gil, Thomas M. Drake , et al. · 2022

Objective Hepatocellular carcinoma (HCC) is increasingly associated with non-alcoholic steatohepatitis (NASH). HCC immunotherapy offers great promise; however, recent data suggests NASH-HCC may be less sensitive to conventional immune chec…

Metabolic dysfunction and cancer in HCV: Shared pathways and mutual interactions Open

Jack Leslie, Daniel Geh, Ahmed M. Elsharkawy, Derek A. Mann, Michèle Vacca · 2022

HCV hijacks many host metabolic processes in an effort to aid viral replication. The resulting hepatic metabolic dysfunction underpins many of the hepatic and extrahepatic manifestations of chronic hepatitis C (CHC). However, the natural h…

Sulfatase-2 from Cancer Associated Fibroblasts: An Environmental Target for Hepatocellular Carcinoma? Open

Marco Y. W. Zaki, Sari F. Alhasan, Ruchi Shukla, Misti McCain, Maja Laszczewska , et al. · 2022

Introduction: Heparin sulphate proteoglycans in the liver tumour microenvironment (TME) are key regulators of cell signalling, modulated by sulfatase-2 (SULF2). SULF2 overexpression occurs in hepatocellular carcinoma (HCC). O…

P099 Serum gamma glutamyl transferase (γGT) – a prognostic biomarker for detrimental neutrophils in patients with hepatocellular carcinoma (HCC)? Open

Marcello Kadharusman, Misti McCain, João Maurício, Maja Laszczewska, Jack Leslie , et al. · 2021

Background Deaths from HCC are rising dramatically in the UK. Immuno-oncology therapies herald a new era of treatment, but only a minority of patients respond. Elevated circulating neutrophils are associated with a poor prognosis, although…

Immunomodulatory Effects of Lenvatinib Plus Anti–Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma Open

Laura Torrens, Carla Montironi, Marc Puigvehí, Agavni Mesropian, Jack Leslie , et al. · 2021

Background and Aims Lenvatinib is an effective drug in advanced HCC. Its combination with the anti‐PD1 (programmed cell death protein 1) immune checkpoint inhibitor, pembrolizumab, has generated encouraging results in phase Ib and is curre…

NAFLD-Associated HCC: Progress and Opportunities Open

Daniel Geh, Quentin M. Anstee, Helen L. Reeves · 2021

Due to an increase in the obesity-associated metabolic syndrome of epidemic proportions, nonalcoholic fatty liver disease (NAFLD) is becoming a leading cause of hepatocellular carcinoma (HCC) in western countries. This presents added chall…

Neutrophils induce paracrine telomere dysfunction and senescence in ROS‐dependent manner Open

Anthony B. Lagnado, Jack Leslie, Marie‐Hélène Ruchaud‐Sparagano, Stella Victorelli, Petra Hirsova , et al. · 2021

Hepatocellular carcinoma in non-alcoholic fatty liver disease—a review of an emerging challenge facing clinicians Open

Daniel Geh, Derek Manas, Helen L. Reeves · 2021

This review highlights how international guidelines, for which NAFLD traditionally has made up a small part of the evidence base, may not be appropriate for all NAFLD-HCC patients. Future guidelines need to reflect the changing landscape o…

Latent Cytomegalovirus Infection and Previous Capsular Polysaccharide Vaccination Predict Poor Vaccine Responses in Older Adults, Independent of Chronic Kidney Disease Open

Nadezhda Wall, Alexandra Godlee, Daniel Geh, Nick D. Jones, Sian Faustini , et al. · 2021

Background Patients with chronic kidney disease (CKD) are more prone to severe infection. Vaccination is a key strategy to reduce this risk. Some studies suggest vaccine efficacy may be reduced in patients with CKD, despite preserved maint…

Tracking neutrophils within the hepatocellular carcinoma microenvironment - development of relevant orthotopic and ex-vivo 3D liver-HCC culture models Open

Daniel Geh, Amy Collins, Caroline Wilson, Helen L. Reeves, Derek A. Mann , et al. · 2020

Weighing the benefits of hepatocellular carcinoma surveillance against potential harms Open

Daniel Geh, Fahd Rana, Helen L. Reeves · 2019

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and usually occurs in people with liver cirrhosis. Both the incidence and mortality of HCC are increasing worldwide, making it a growing public health issue. HCC diagno…

ADWE-01 The prediction of diminutive/small polyp histology using didactic vs computer based training in gastroenterology trainees Open

Graham Baker, Samuel C. Smith, Marietta Iacucci, John R. Saltzman, Uday N. Shivaji , et al. · 2018

Introduction Experts are able to predict and differentiate between neoplastic and non-neoplastic colonic polyps with high accuracy and meet the PIVI (Preservation and Incorporation of Valuable Endoscopic Innovations) thresholds. However, t…

Tu1037 A RANDOMIZED CONTROLLED STUDY OF THE PREDICTION OF DIMINUTIVE/SMALL POLYP HISTOLOGY USING DIDACTIC VS. COMPUTER BASED SELF-LEARNING MODULE IN GASTROENTEROLOGY TRAINEES Open

Samuel C. Smith, John R. Saltzman, Uday N. Shivaji, Brendan Cord Lethebe, Ayman Bannaga , et al. · 2018

Biliary epithelium and liver B cells exposed to bacteria activate intrahepatic MAIT cells through MR1 Open

Hannah C. Jeffery, Bonnie van Wilgenburg, Ayako Kurioka, Krishan Parekh, Kathryn Stirling , et al. · 2015

Cardiac magnetic resonance imaging: a tool to diagnose parasitic infection? Open

Alexander Loch, Daniel Geh, Ramesh Singh Veriah · 2015

A 48-year-old Somali camel farmer presented with symptoms of heart failure. He reported a 1 year history of exertional dyspnoea, loss of appetite, and weight loss. Clinically, there were signs of right heart failure with ascites and spleno…

Daniel Geh YOU? Author Swipe